경카테터 심장판막 시장 규모, 점유율, 동향 분석 리포트 : 용도별, 기술별, 지역별, 부문별 예측(2025-2033년)

Transcatheter Heart Valve Market Summary

The global transcatheter heart valve market size was estimated at USD 5.49 billion in 2024 and projected to reach USD 21.24 billion by 2033, growing at a CAGR of 16.49% from 2025 to 2033. The rising prevalence of heart valve diseases, particularly in the aging population, is driving the demand for transcatheter heart valve (THV) procedures, such as TAVR, especially for conditions such as aortic stenosis and mitral regurgitation.

Key factors propelling the growth of the transcatheter heart valve industry include continuous improvements in THV design, advancements in imaging and delivery systems, and the increasing preference for minimally invasive surgeries, which offer shorter recovery times, reduced complications, and lower healthcare costs compared to traditional open-heart surgery.

In September 2024, the CDC reported that 75% of adults in the U.S. have limited knowledge about heart valve disease. This lack of awareness extends to high-risk groups, particularly individuals aged 65 and older. Each year, over 5 million people in the U.S. receive a diagnosis of heart valve disease, contributing to more than 25,000 fatalities attributed to this condition annually.

The growing prevalence of heart valve diseases, particularly in the aging population, significantly drives the demand for transcatheter heart valve (THV) procedures. Conditions such as aortic stenosis and mitral regurgitation are becoming more common, necessitating advanced treatment solutions such as THVs. In September 2024, the CDC reported that 75% of adults in the U.S. have limited knowledge about heart valve disease. This lack of awareness extends to high-risk groups, particularly individuals aged 65 and older. Each year, over 5 million people in the U.S. receive a diagnosis of heart valve disease, contributing to more than 25,000 fatalities attributed to this condition annually.

Continuous improvements in THV design, including enhanced valve durability, ease of implantation, and improved patient outcomes, are crucial drivers. Advancements in imaging techniques and valve delivery systems have also significantly improved procedural success and expanded the patient pool eligible for THV procedures. In August 2024, Boston Scientific announced that its ACURATE Prime Aortic Valve System has received CE mark approval. This state-of-the-art transcatheter aortic valve replacement system features a new valve size to serve patients with larger anatomies and is indicated for individuals at low, intermediate, and high risk experiencing severe aortic stenosis. The system features a self-expanding design and a refined deployment mechanism, enhancing the accuracy of valve positioning to improve overall patient outcomes.

Global Transcatheter Heart Valve Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global transcatheter heart valve market report based on application, technology, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Transcatheter Aortic Valve
• Transcatheter Pulmonary Valve
• Transcatheter Mitral Valve
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Balloon Expanded Transcatheter Valve
• Self-Expanded Transcatheter Valve
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Technology
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Transcatheter Heart Valve Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of valvular heart diseases and aging population
    • 3.2.1.2. Increasing preference for minimally invasive cardiac procedures
    • 3.2.1.3. Technological advancements in valve design and delivery systems
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High procedural and device costs limiting accessibility
    • 3.2.2.2. Complications related to valve durability and thrombosis risk
  • 3.2.3. Market developments
    • 3.2.3.1. Key clinical trials in the transcatheter heart valve market, by region
    • 3.2.3.2. Recent product launches in the transcatheter heart valve market, by region
    • 3.2.3.3. Emerging products in the transcatheter heart valve market, by region
  • 3.2.4. Competitive factors and strategies
    • 3.2.4.1. Clinical insights
    • 3.2.4.2. Emerging technologies
    • 3.2.4.3. Market appeal
    • 3.2.4.4. Physician training and marketing
    • 3.2.4.5. Product improvements and innovations
    • 3.2.4.6. Mergers, acquisitions, and partnerships
    • 3.2.4.7. Product portfolio management
• 3.3. Transcatheter Heart Valve Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Transcatheter Heart Valve Market: Application Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Application Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Transcatheter Aortic Valve
  • 4.4.1. Transcatheter aortic valve market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Transcatheter Pulmonary Valve
  • 4.5.1. Transcatheter pulmonary valve market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Transcatheter Mitral Valve
  • 4.6.1. Transcatheter mitral valve market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Transcatheter Heart Valve Market: Technology Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Balloon Expanded Transcatheter Valve
  • 5.4.1. Balloon expanded transcatheter valve market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Self-Expanded Transcatheter Valve
  • 5.5.1. Self-expanded transcatheter valve market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Transcatheter Heart Valve Market: Regional Estimates & Trend Analysis by Application and Technology

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. Key company market share analysis, 2024
  • 7.2.2. Medtronic
    • 7.2.2.1. Overview
    • 7.2.2.2. Financial Performance
    • 7.2.2.3. Product Benchmarking
    • 7.2.2.4. Strategic Initiatives
  • 7.2.3. Abbott
    • 7.2.3.1. Overview
    • 7.2.3.2. Financial Performance
    • 7.2.3.3. Product Benchmarking
    • 7.2.3.4. Strategic Initiatives
  • 7.2.4. Braile Biomedica
    • 7.2.4.1. Overview
    • 7.2.4.2. Financial Performance
    • 7.2.4.3. Product Benchmarking
    • 7.2.4.4. Strategic Initiatives
  • 7.2.5. Meril Life Sciences Pvt. Ltd., Inc.
    • 7.2.5.1. Overview
    • 7.2.5.2. Financial Performance
    • 7.2.5.3. Product Benchmarking
    • 7.2.5.4. Strategic Initiatives
  • 7.2.6. Edwards Lifesciences Corporation
    • 7.2.6.1. Overview
    • 7.2.6.2. Financial Performance
    • 7.2.6.3. Product Benchmarking
    • 7.2.6.4. Strategic Initiatives
  • 7.2.7. MicroPort Scientific Corporation
    • 7.2.7.1. Overview
    • 7.2.7.2. Financial Performance
    • 7.2.7.3. Product Benchmarking
    • 7.2.7.4. Strategic Initiatives
  • 7.2.8. Venus Medtech (Hangzhou) Inc.
    • 7.2.8.1. Overview
    • 7.2.8.2. Financial Performance
    • 7.2.8.3. Product Benchmarking
    • 7.2.8.4. Strategic Initiatives
  • 7.2.9. JenaValve
    • 7.2.9.1. Overview
    • 7.2.9.2. Financial Performance
    • 7.2.9.3. Product Benchmarking
    • 7.2.9.4. Strategic Initiatives
  • 7.2.10. Biosensors International Group, Ltd
    • 7.2.10.1. Overview
    • 7.2.10.2. Financial Performance
    • 7.2.10.3. Product Benchmarking
    • 7.2.10.4. Strategic Initiatives
  • 7.2.11. HLT Medical (Bracco)
    • 7.2.11.1. Overview
    • 7.2.11.2. Financial Performance
    • 7.2.11.3. Product Benchmarking
    • 7.2.11.4. Strategic Initiatives